



- (51) **International Patent Classification:**
G16H 20/10 (2018.01) *A61K 40/31* (2025.01)
- (21) **International Application Number:**
PCT/IB2024/061734
- (22) **International Filing Date:**
22 November 2024 (22.11.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/602,289 22 November 2023 (22.11.2023) US
63/602,356 22 November 2023 (22.11.2023) US
63/602,359 22 November 2023 (22.11.2023) US
63/606,827 06 December 2023 (06.12.2023) US
63/606,880 06 December 2023 (06.12.2023) US
- (71) **Applicant:** JANSSEN BIOTECH, INC. [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US).
- (72) **Inventors:** MAGGE RANGANATHA, Arjun; 920 US
Route 200, Raritan, New Jersey 08869 (US). JAVIDI, Alex;

920 US Route 200, Raritan, New Jersey 08869 (US). LU, Hoang; 920 US Route 200, Raritan, New Jersey 08869 (US). HENCKELS, Eric; 920 US Route 200, Raritan, New Jersey 08869 (US). YANG, Katherine; 920 US Route 200, Raritan, New Jersey 08869 (US). BERK, Erik; 920 US Route 200, Raritan, New Jersey 08869 (US). SHEN, Dee; 920 US Route 200, Raritan, New Jersey 08869 (US). SZTANKA-TOTH, Tamas; Johnson & Johnson Platz 1, Neuss (DE).

- (74) **Agent:** LANE, David A. et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

- (54) **Title:** MANUFACTURING SYSTEMS, METHODS, AND AI MODELS FOR OPTIMIZING CAR T DRUG PRODUCTS




FIG. 4

- (57) **Abstract:** Embodiments herein relate to patient characteristics that are indicative of CAR-T cell manufacturing qualities. In certain aspects, parameters are collected and input through a trained algorithm to determine various attributes of the CAR T drug product. Such determinations may be used to optimize the manufacturing process for the CAR T drug product by adjusting various manufacturing parameters.

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*